El-Khoueiry, MD, discussed nivolumab plus ipilimumab vs lenvatinib/sorafenib in unresectable HCC. Immunotherapy has become a ...
Transcatheter arterial chemoembolization plus donafenib and sintilimab for unresectable hepatocellular carcinoma: A prospective, single-arm, phase II study. Treatment response of the enrolled HCC ...
HealthDay News — For patients with resected stage IIIB-C or stage IV melanoma, recurrence-free survival is longer with nivolumab than ipilimumab, according to a study published online Oct. 18 in the ...
Please provide your email address to receive an email when new articles are posted on . The 7-year intracranial progression free-survival among patients treated with combination therapy was 42%.
Nivolumab and ipilimumab combination approved for microsatellite instability-high or mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC), showing significant progression-free ...
A Prescription Drug User Fee Act target date of June 23, 2025 has been set for the application. The sBLA is supported by data from the randomized, open-label phase 3 CheckMate 8HW trial ...
Trend and Provider- and Organizational-Level Factors Associated With Early Palliative Care Billing Among Patients Diagnosed With Distant-Stage Cancers in 2010-2019 in the United States Patients with ...
Based on the Phase 3 CheckMate-9DW trial, Opdivo plus Yervoy demonstrated a statistically significant overall survival benefit compared to investigator’s choice of lenvatinib or sorafenib 1 In the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback